Status:
COMPLETED
PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Metastatic Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE1
Brief Summary
This pilot study will investigate the use of PSMA-PET/MRI (Positron Emission Tomography/ Magnetic Resonance Imaging)to guide radiation treatment planning in patients with known or suspected locally me...
Eligibility Criteria
Inclusion
- Biopsy-proven treatment-naïve prostate adenocarcinoma with pelvic metastases known to suspected on standard-of-care staging imaging
- Eligibility and plan to undergo definitive radiation therapy for prostate cancer per established standard-of-care radiation oncology clinical guidelines
- Be at least 18 years of age
Exclusion
- Inability to tolerate or undergo PET/MRI or PET/CT
- Previous or current hematologic or lymphatic disorder (including leukemia, lymphoma, Castleman's disease, etc.)
- Recurrent prostate adenocarcinoma
- Known distant metastatic disease
- Current or prior treatment for prostate cancer
- Known allergy to glucagon
- Previous diagnosis of insulinoma or pheochromocytoma
Key Trial Info
Start Date :
August 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 23 2022
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04086966
Start Date
August 20 2020
End Date
February 23 2022
Last Update
April 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham Medical Center
Birmingham, Alabama, United States, 35249